New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Revenue increased 11.4 per cent to Rs. 8,545 crore
Subscribe To Our Newsletter & Stay Updated
